PDSB - PDS Biotechnology Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
-0.55 (-7.64%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close7.20
Bid0.00 x 1300
Ask6.98 x 900
Day's Range6.38 - 7.15
52 Week Range5.03 - 25.40
Avg. Volume208,903
Market Cap34.43M
Beta (3Y Monthly)3.41
PE Ratio (TTM)N/A
EPS (TTM)-0.28
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • Benzinga4 days ago

    Learning When To Pick Your Battles Starts With Winning Setups

    My biggest winning trades from Wednesday on PDS Biotechnology Corp (NASDAQ: PDSB) came on a handful of pullback trades. Given that, I wanted to spend some time this week analyzing my timing on these pullback trades to illustrate how timing and the qualities of a stock play in the success and failure of a pullback strategy. Given the apparent momentum, I waited for the first pullback on rising volume and got in on the break above the $7.50 closing high.

  • GlobeNewswire6 days ago

    PDS Biotechnology Announces Publication Supporting Novel Mechanisms of Action of its Proprietary Versamune® Platform in Cancer Immunotherapy

    PDS Biotechnology Corporation (“PDS Biotechnology”) (PDSB), a clinical-stage immuno-oncology company pioneering the development of multifunctional immunotherapeutic products, today announced a peer-reviewed publication supporting the novel mechanisms of action of its proprietary Versamune® platform in cancer immunotherapy. The article “Antigen Priming with Enantiospecific Cationic Lipid Nanoparticles Induces Potent Antitumor CTL Responses through Novel Induction of a Type I IFN Response” was published online on May 3, 2019 in the Journal of Immunology, and describes the way PDS’ Versamune® platform recruits and activates killer T-cells to recognize and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack.

  • Associated Press7 days ago

    PDS Biotechnology: 1Q Earnings Snapshot

    The Berkeley Heights, New Jersey-based company said it had profit of $1.47 per share. Losses, adjusted for non-recurring gains, came to $1.07 per share. PDS Biotechnology shares have declined slightly ...

  • GlobeNewswire7 days ago

    PDS Biotechnology Reports First Quarter 2019 Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., May 14, 2019 -- PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development.

  • GlobeNewswirelast month

    PDS Biotechnology Appoints Stephen Glover to its Board of Directors

    PDS Biotechnology Corporation (PDSB), a clinical-stage immuno-oncology company developing novel multifunctional immunotherapeutic products, today announced that Stephen Glover has been appointed to PDS’s Board of Directors, effective immediately. Mr. Glover has been appointed to serve as a member of the Board of Directors’ audit committee and compensation committee. Mr. Glover has more than 30 years of experience in the biopharmaceutical industry, specializing in developing pharmaceutical business strategies, corporate and product development, and commercialization and business optimization.